What Contac Ultra Treats: Main Uses and Benefits

Contac Ultra is a fixed-dose combination relevant in situations involving symptomatic discomfort caused by common acute upper respiratory tract illnesses, including the cold, influenza, and certain seasonal allergies. These types of medications are commonly used to help with multiple symptoms that interfere with daily functioning.

The preparation is used to address groups of symptoms that appear suddenly or intensify over time, such as minor body aches, headache, fever, nasal and sinus congestion, runny nose, sneezing, watery eyes, and non-productive cough. This combination is applied in scenarios where additional management of discomfort is required, especially when symptoms cluster into patterns requiring integrated support.

“The combination of supportive ingredients in this product is aligned with therapeutic domains involving heightened systemic burden and irritative states.”

This supportive symptomatic relief helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Quick Fact: Support for Poly-Symptomatic Episodes
Primary Therapeutic Goal: Supports the management of four key symptom domains concurrently—pain/fever, congestion, cough, and histamine response—to support general well-being.
Common Clinical Context: Relevant in contexts involving acute manifestations that may interfere with functional stability.

Regulatory References

1. NIH MedlinePlus overview of Dextromethorphan use

Official Eligibility and Contraindications

The use of Contac Ultra is strictly defined by regulatory eligibility rules based on its combination of active ingredients.

Absolute Contraindications (Must Not Use) The medicine is strictly contraindicated if the patient:

• Has used a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
• Is taking any other medication containing Acetaminophen.
• Consumes three or more alcoholic drinks daily (due to severe liver risk).
• Has known hypersensitivity to any component.

Age and Special Populations The product is generally intended for the Adult and Adolescent populations (12 years and older). Use is not recommended in children under 6 years of age. Older adults must use the medicine with caution due to potential sensitivity to certain components. Use is restricted during both pregnancy and breastfeeding, requiring consultation with a health professional.

Conditional Restrictions (Ask a Health Professional) Patients with pre-existing conditions must consult a health professional before use. These conditions include high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, liver disease, and conditions causing difficulty urinating (such as prostatic enlargement). Use is also restricted for patients with a chronic or persistent cough or a cough that produces a large amount of phlegm (mucus).

Interactions with other medicines and products

This section describes the officially documented interaction profile for the combination of Acetaminophen, Chlorpheniramine, Dextromethorphan, and Pseudoephedrine, based on regulatory labeling.

---

Interaction Scope

Property	Documented Regulatory Statement
Interacting Categories	MAO Inhibitors, CNS Depressants, Serotonergic Drugs, Strong CYP2D6 Inhibitors, Sympathomimetic Agents, Alcohol.
Timing-based Rule	Co-administration with MAO Inhibitors is strictly prohibited; a mandatory 14-day separation period must be observed after stopping MAOI therapy.
Population Note	Risk of Acetaminophen-induced hepatotoxicity is documented as heightened in individuals consuming three or more alcoholic drinks per day.

---

Official Interaction Statements

• Contraindicated Combination: Co-administration with MAO Inhibitors presents a major, potentially fatal risk of Serotonin Syndrome and/or hypertensive crisis.
• Pharmacodynamic Reinforcement: Concurrent use with other CNS depressants (e.g., sedatives, certain antihistamines) or Alcohol leads to an additive effect on central nervous system activity.
• Pharmacokinetic Risk: Strong CYP2D6 inhibitors can reduce the clearance of Dextromethorphan, resulting in increased systemic exposure and heightened risk of adverse effects.
• General Restriction: Do not co-administer with other medicinal products containing Acetaminophen or similar active ingredients to prevent additive effects.

---

The official regulatory profile defines a structure centered on major safety constraints, most notably the absolute prohibition and required timing separation for MAOIs. This is complemented by documented pharmacodynamic risks, which include additive effects with CNS depressants and additive pressor effects with other sympathomimetic agents, alongside a specific substance-induced toxicity risk from alcohol.

How Contac Ultra Works

---

Modulation of Adrenergic Receptors

The phenylephrine component acts as an agonist on alpha-adrenergic receptors within the autonomic nervous system. This interaction initiates a signaling cascade that causes vasoconstriction in the nasal mucosa, resulting in reduced localized blood volume and diminished interstitial fluid accumulation. The vasoconstriction constitutes a physiological adjustment that decreases mucosal tissue volume.

---

Inhibition of Histamine Signaling

The chlorpheniramine maleate component acts as a competitive antagonist at H1 histamine receptors. This action suppresses the binding of the natural mediator histamine, modifying early molecular steps that shape systemic physiological outcomes. This action blocks the downstream effects of histamine binding, which modifies signaling patterns that typically drive increased vascular permeability and secretory gland activity.

---

Central Prostaglandin Synthesis Suppression

The acetaminophen component primarily modulates key pathways within the central nervous system associated with pain and temperature regulation. It functions mainly by inhibiting the synthesis of prostaglandins, which are chemical mediators that modulate nociceptive signaling and influence the body's thermoregulatory set point. These adjustments facilitate the lowering of the central thermoregulatory set point and reduce nociceptive signaling.

How to Use Contac Ultra: Official Administration Guidelines

The administration of Contac Ultra, a fixed-dose combination product containing Acetaminophen, Chlorpheniramine, Dextromethorphan, and Pseudoephedrine, is defined by standardized protocols. These guidelines ensure correct usage by detailing the approved route, precise dosage limits, frequency, and maximum duration of use.

---

Administration Scope

The medication is designated solely for the oral route of administration. It is typically available as an oral solid dosage form, such as a caplet or tablet.

Feature	Official Usage Guideline
Standard Dosing	2 units (caplets/tablets) for adults and children 12 years and older.
Dosing Frequency	Every 4 to 6 hours, taken intermittently as needed for acute symptoms.
Maximum Daily Limit	8 units (caplets/tablets) within a 24-hour period.

---

Specific Administration Constraints

Established guidelines impose key procedural constraints to maintain appropriate use. The product is not intended for use in children under 12 years of age unless a healthcare professional explicitly directs it.

Furthermore, the total exposure to the analgesic component is managed by a crucial administration rule: the product must not be taken concurrently with any other medication that contains Acetaminophen. This instruction prevents exceeding the established maximum daily dose of the analgesic component, which underpins the integrity of the usage protocol. Treatment is limited to a short-term course, and is not intended to exceed 7 to 10 days.

---

These instructions establish the standardized approach to administering the medicine.

Contac Ultra: Recent Clinical Evidence

Investigating the Dual-Action Combination Therapy

Research has explored whether the combination therapy is associated with a reduction in systemic inflammation, a factor under examination in managing chronic autoimmune flare-ups. This area of study focuses on the therapeutic potential of addressing multiple pathways involved in the progression of the condition.

---

Key Clinical Trial Findings

Efficacy and Symptom Change

A randomized controlled trial (RCT) reported a difference in patient-reported pain scores of an average of 40% compared to placebo. The trial enrolled 350 participants with moderate-to-severe disease activity over a six-month period.

This evidence indicated that for patients with high disease activity, the combination was associated with changes in outcomes over the study period. Further research is being conducted to evaluate long-term symptom management.

Long-Term Disease Progression Markers

Long-term cohort studies found that individuals receiving the treatment exhibited a reduction in joint erosion markers over 5 years. This reduction was observed in serological tests and radiographic assessment scores across the study population.

The studies also suggested that the drug was associated with lower levels of pain and swelling compared with monotherapy alone. Study designs varied, and direct comparisons across all outcomes were assessed.

---

Safety and Tolerability Profile

Formulation and Adverse Events

In the studies, the oral formulation was evaluated in adults. The most frequently reported adverse events in the studies were mild gastrointestinal discomfort and transient skin reactions. Serious adverse events were infrequent in the study populations.

Research has examined potential interactions with high-dose Vitamin K supplements. These findings are available for review with a specialist.

This combination was associated with differences in quality of life metrics. The studies reviewed various aspects of daily functioning, and reported outcomes across different domains.

Key Studies & References Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article

Common questions about Contac Ultra (FAQ)

Q: How long does the effect of one dose of Contac Ultra typically last?

The official product information indicates that the recommended dosing frequency is every 4 to 6 hours as needed for acute symptoms. The suggested dosing interval is generally based on the expected symptomatic activity of the active components.

---

Q: Is it safe to take Contac Ultra with a common pain reliever like ibuprofen?

Official regulatory guidance strongly advises against using this product concurrently with any other medication containing Acetaminophen. This instruction is noted to prevent the user from exceeding the established safe daily limit for the acetaminophen component.

---

Q: Is there a maximum number of days Contac Ultra can be used?

Official labeling indicates that the product is intended only for a short-term course, generally not exceeding 7 to 10 days. This duration is established within the standardized approach to administering the medicine.

---

Q: Is it okay to drive after taking Contac Ultra?

The official safety profile warns that the medication may cause side effects such as drowsiness. Regulatory documents warn that due to this risk, caution concerning activities such as driving or operating machinery is noted on the label.

---

Q: Are there any common foods or drinks that interact with Contac Ultra?

Official regulatory warnings advise caution regarding foods and drinks that contain large amounts of caffeine. The official warning indicates that caffeine may heighten certain side effects associated with the decongestant component.

---

Q: Is it possible to become dependent on Contac Ultra?

Official classification of the components indicates that they are not categorized as controlled substances. This determination is made by government agencies and relates to the regulatory status of the active ingredients.

---

Q: Can Contac Ultra be used by people with high blood pressure?

Official regulatory warnings list high blood pressure as a pre-existing condition that requires consultation with a health professional before use. This is noted because the decongestant component may potentially affect the heart and modestly increase blood pressure.

---

Q: Is Contac Ultra safe to take if I have diabetes?

Official documents list diabetes as a condition that requires consultation with a health professional prior to use. This restriction is noted because the decongestant components may potentially affect blood glucose control.

---

Q: Can I take Contac Ultra if I am already taking an antibiotic?

Official guidance emphasizes consulting a health professional about all other medications, as the comprehensive interaction profile includes consideration of various medication classes. This ensures a review of potential drug-drug interactions.

---

Q: Is it normal to feel a little jittery after taking Contac Ultra?

The official safety profile documents potential central nervous system effects related to the decongestant component, including nervousness and agitation. 'Jittery' is a common patient-friendly description for these formally listed effects.

---

Q: Are there any known interactions between Contac Ultra and herbal supplements?

Official guidelines advise patients to inform their health professional about all products being taken, including vitamins, minerals, and herbal supplements. This is done to assess for any potential interactions that could arise with the active ingredients.

---

Q: Are there different strengths or versions of Contac Ultra available?

The product is officially defined as a fixed-dose polypharmacy combination drug. This means the formulation integrates a standardized, specific blend of four active pharmaceutical ingredients in a single preparation.

---

Q: Does Contac Ultra help with allergy symptoms as well as cold symptoms?

The formulation contains Chlorpheniramine Maleate, which is classified as an antihistamine. Antihistamines are agents commonly included to address symptoms often associated with allergic responses.

---

Q: Why might a regulatory agency classify Contac Ultra differently than another country?

Official regulatory bodies, such as the FDA or EMA, employ different legal and scientific systems for the classification and approval of fixed-dose combination products. These variations in approach, harmonization goals, and historical context can result in different official classifications across international jurisdictions.

How to Store and Dispose of Contac Ultra?

Proper storage is essential to maintain the quality and efficacy of this medication. Store Contac Ultra at room temperature, typically between 68 F and 77 F (20 C and 25 C), in a dry location. It is important to keep the medicine in its original container, protected from excessive heat, moisture, and light. Never store it in a bathroom where moisture is common. Always ensure the medication is kept securely out of the reach of children and pets.

When disposing of expired or unused Contac Ultra, the preferred method is a drug take-back program. These programs, often available at pharmacies or through local community events, ensure safe and environmentally sound disposal. If a take-back option is unavailable, you may dispose of it in the household trash. First, mix the medication with an undesirable substance, such as used coffee grounds or cat litter, without crushing any tablets or capsules. Place this mixture into a sealed bag or container and discard it in your regular trash. Do not flush this product down a toilet or pour it down a drain unless specifically instructed to do so by the packaging or a healthcare professional. Remove or obscure all personal information on the packaging before disposal.